Drug Transporters: The Final Frontier for Drug Interactions

DECEMBER 01, 2008
John R. Horn, PharmD, FCCP, and Philip Hansten, PharmD

Drs. Horn and Hansten are both professors of pharmacy at the University of Washington School of Pharmacy. For an electronic version of this article, including references if any, visit www.hanstenandhorn.com.

The knowledge of the specific enzymes responsible for drug metabolism has expanded over the past 15 years. We now understand that many drugs are actively transported into and out of cells by a variety of transporter proteins susceptible to reduced or enhanced activity upon exposure to certain drugs.

Drug transporters are usually either uptake or efflux. The Figure shows some of the transporters found at the apical (luminal) side of the enterocytes in the small intestine. P-glycoprotein (P-gp) is an efflux transporter that takes drug molecules from the cell cytoplasm and transports them back into the intestinal lumen for excretion. For some orally administered drugs, this limits their bioavailability. The organic anion transporting polypeptide and organic cation transporter are uptake transporters that mediate the transport of molecules into the cell. In addition to the enterocyte, these and other transporters are found on the apical side of renal tubular cells and the bile canaliculi. Transporters can also be found on the luminal surface of capillary endothelial cells in the brain and in renal tubular cells.

P-gp transports many drugs that are substrates of CYP3A4. When a drug that is a substrate of P-gp and CYP3A4 is taken orally, it has to diffuse through the enterocytes to gain access to the systemic circulation. P-gp and CYP3A4 act as barriers to the systemic exposure of exogenous substances including drugs. Some drug molecules will be transported out of the enterocyte by P-gp and be eliminated without absorption. Other molecules will be metabolized by CYP3A4 in the enterocyte and lost to pharmacologic activity. P-gp helps modulate the number of drug molecules in the enterocyte and therefore helps to prevent saturation of CYP3A4. This results in an increase in the efficiency of first-pass drug metabolism. CYP3A4 concentrations decrease from the proximal to distal portions of the intestine. P-gp content increases from the proximal to distal intestine. Thus, where an excess of CYP3A4 is available for metabolism, less P-gp is present. Conversely, where CYP3A4 concentrations are lower, more P-gp is found to prevent saturation of the enzyme.

An inhibitor of P-gp will increase the bioavailability of a P-gp substrate, whereas induction of P-gp will reduce the bioavailability of a substrate drug. Digoxin is a drug that is a substrate of P-gp but is not metabolized by CYP3A4. P-gp inhibits its bioavailability and contributes to its renal and biliary secretion.

The coadministration of the P-gp inhibitors erythromycin or clarithromycin to patients receiving chronic digoxin has been noted to result in an increase in serum digoxin concentrations.1 In another study, clarithromycin increased the area under the plasma concentration- time curve (AUC) following oral digoxin administration by about 1.7-fold.2 The AUC of digoxin administered intravenously was increased 1.2-fold during clarithromycin dosing.

The ability of quinidine to increase digoxin concentrations has been well described. Quinidine not only increases the bioavailability of digoxin, it also reduces the biliary and renal secretion of digoxin by inhibiting P-gp activity. Because P-gp is present in the endothelium of capillaries in the brain and functions as part of the blood?brain barrier, a P-gp inhibitor may enable a greater percentage of digoxin to reach the brain causing increased central nervous system side effects. Conversely, P-gp inducers can reduce digoxin plasma concentrations."

Substrates, Inhibitors, and Inducers of P-glycoprotein












St. John's wort











  1. Eberl S, Renner B, Neubert A, et al. Role of P-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet. 2007;46(12):1039-1049.
  2. Rengelshausen J, Goggelmann C, Burhenne J, et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 2003;56(1):32-38.
  3. Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52(7):772-779.